Press Releases

09-26-2023	Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis
09-25-2023	Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis
09-15-2023	Pliant Therapeutics Appoints Minnie Kuo as Chief Development Officer
09-11-2023	Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023
08-30-2023	Pliant Therapeutics to Participate in Upcoming Investor Conferences
08-28-2023	Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023
08-09-2023	Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
08-09-2023	Pliant Therapeutics Announces Initiation of BEACON-IPF, a Phase 2b Clinical Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis
07-25-2023	Pliant Therapeutics to Participate in Upcoming Investor Conferences
06-23-2023	Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™